275 related articles for article (PubMed ID: 12833153)
1. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
Coggins BE; Li X; McClerren AL; Hindsgaul O; Raetz CR; Zhou P
Nat Struct Biol; 2003 Aug; 10(8):645-51. PubMed ID: 12833153
[TBL] [Abstract][Full Text] [Related]
2. Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design.
Coggins BE; McClerren AL; Jiang L; Li X; Rudolph J; Hindsgaul O; Raetz CR; Zhou P
Biochemistry; 2005 Feb; 44(4):1114-26. PubMed ID: 15667205
[TBL] [Abstract][Full Text] [Related]
3. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 2001 Jan; 40(2):514-23. PubMed ID: 11148046
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
Whittington DA; Rusche KM; Shin H; Fierke CA; Christianson DW
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8146-50. PubMed ID: 12819349
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
Miller MD; Gao N; Ross PL; Olivier NB
Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
[TBL] [Abstract][Full Text] [Related]
8. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
9. Exploring the UDP pocket of LpxC through amino acid analogs.
Hale MR; Hill P; Lahiri S; Miller MD; Ross P; Alm R; Gao N; Kutschke A; Johnstone M; Prince B; Thresher J; Yang W
Bioorg Med Chem Lett; 2013 Apr; 23(8):2362-7. PubMed ID: 23499237
[TBL] [Abstract][Full Text] [Related]
10. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
11. Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design.
Kalinin DV; Holl R
Curr Top Med Chem; 2016; 16(21):2379-430. PubMed ID: 27072691
[TBL] [Abstract][Full Text] [Related]
12. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
[TBL] [Abstract][Full Text] [Related]
13. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
14. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
15. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of the zinc-dependent deacetylase in the lipid A biosynthetic pathway.
McClerren AL; Zhou P; Guan Z; Raetz CR; Rudolph J
Biochemistry; 2005 Feb; 44(4):1106-13. PubMed ID: 15667204
[TBL] [Abstract][Full Text] [Related]
17. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
[TBL] [Abstract][Full Text] [Related]
19. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
[TBL] [Abstract][Full Text] [Related]
20. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
